Literature DB >> 2869721

Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients.

Y J Sohn, A F Bencini, A H Scaf, U W Kersten, S Agoston.   

Abstract

Plasma concentrations and the degree of neuromuscular blockade after a 2-min infusion of 0.1 mg/kg of vecuronium bromide or pancuronium bromide (equipotent doses) were studied in 12 gynecologic patients. The plasma concentrations of both drugs declined in a triphasic manner. The difference between the intercepts and rate constants of the two drugs was not significant. Vecuronium was removed faster from the plasma than pancuronium; this was reflected in a significantly larger plasma clearance rate for vecuronium (4 ml X min-1 X kg-1 vs 1.1 ml X min-1 X kg-1 for pancuronium). The effective plasma concentrations at 50% recovery of the twitch height were 0.11 +/- 0.02 (vecuronium) and 0.2 +/- 0.03 microgram/ml (pancuronium). The disposition kinetics were adequately described by a three-compartment model. An effect compartment was added to the model to correlate the neuromuscular effects and plasma concentrations of both drugs. The ratio between concentrations of vecuronium and pancuronium in the effect compartment at 50% twitch height was 0.83. In spite of its greater potency, vecuronium has a shorter duration of action than pancuronium.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869721

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  19 in total

1.  Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?

Authors:  T M Beaufort; J H Proost; K Kuizenga; M C Houwertjes; U W Kleef; J M Wierda
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

Review 2.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 3.  [Effect compartment equilibration and time-to-peak effect. Importance of a pharmacokinetic-pharmacodynamic principle for the daily clinical practice].

Authors:  J Bruhn; P M Schumacher; T W Bouillon
Journal:  Anaesthesist       Date:  2005-10       Impact factor: 1.041

4.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

5.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

Review 6.  A simulation of neuromuscular function and heart rate during induction, maintenance, and reversal of neuromuscular blockade.

Authors:  R R Jaklitsch; D R Westenskow
Journal:  J Clin Monit       Date:  1990-01

Review 7.  Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations.

Authors:  D K Meijer; W E Mol; M Müller; G Kurz
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

8.  Pharmacokinetic-pharmacodynamic modeling of doxacurium: effect of input rate.

Authors:  Y Zhu; G Audibert; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

9.  Digoxin infusion versus bolus injection in rapid atrial fibrillation: relation between serum level and response.

Authors:  A J Smit; A H Scaf; L H van Essen; K I Lie; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Pharmacokinetics of pancuronium in patients undergoing coronary artery surgery with and without low dose dopamine.

Authors:  J M Wierda; P J van der Starre; A H Scaf; W D Kloppenburg; J H Proost; S Agoston
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.